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Background and Objective: Renal denervation has
recently become of great interest as a potential treatment
for resistant hypertension. Denervation techniques using
radio frequency (RF) or ultrasound energy sources have
already been explored in literature. In this study, we
investigate the use of lasers as a potential energy source for
renal denervation. In vitro studies are performed in
porcine/ovine renal arteries with focused laser beams at
980nm, 1210nm, and 1700nm to study the ability to
damage renal nerves without causing injury to non-target
tissue structures like the endothelium. Then, a 980nm
laser catheter prototype is built and used to demonstrate in
vivo renal denervation in ovine renal arteries.
Subjects and Methods: This study utilizes fiber coupled
infrared lasers at 980nm, 1210nm, and 1700nm. In vitro
laser denervation studies at 980nm are performed in both
porcine and ovine renal arteries to study the ability of
focused laser beams to damage renal nerves without
injuring the endothelium. In vitro studies using lasers
close to the lipid absorption lines at 1210nm and 1700nm
are also performed in porcine renal arteries to study the
possibility of selectively damaging the renal nerves by
targeting the lipidmyelin sheaths surrounding the nerves.
Then, a laser catheter prototype is designed and built for in
vivo renal denervation in ovine renal arteries using the
980nm laser (powers ranging from 2 to 4W, 5 seconds per
exposure).Histochemical evaluations of the frozen sections
are performed using methylthiazolyldiphenyl-tetrazolium
bromide (MTT) assay.
Results: Histochemical analysis of in vitro laser treat-
ments at 980nm in porcine and ovine renal arteries show
clear evidence of laser-induced renal nerve damage
without injury to the endothelium and part of the media.
No evidence of selective nerve damage is observed using
the 1210nm and 1700nm lasers with the current
treatment parameters. Histochemical analysis of in vivo
laser treatments in ovine renal arteries using a focused
980nm laser show clear evidence of renal nerve damage
with depths of damage extending> 1.5mm from the artery
wall. Sections with laser-induced damage to the media/
adventitia at depths of> 1mm without injury to the
endothelium are also observed.
Conclusions:Wedemonstrate the use of focused lasers as
an attractive energy source for causing renal nerve
damage without injury to the artery wall and thus, may
have potential therapeutic applications for conditions such
as resistant hypertension, where renal denervation has
been shown to be a promising form of treatment. Lasers
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INTRODUCTION
Hypertension is a major global health concern with an
estimated one third of the adult population in the
developedworld suffering from this condition [1,2]. Despite
the availability of numerous effective pharmacologic
agents and efforts to diagnose hypertension, only half of
the treated patients are controlled to established blood
pressure targets [2–4]. Using the National Health and
Nutrition Examination Survey data collected from
2003–2008, Persell estimated the prevalence of resistant
hypertension to be 12.8% of all US adults being treated for
hypertension [5]. Pimenta et al., estimate a prevalence of
resistant hypertension among patients treated for
hypertension to be 15–30% based on results from clinical
trials and more recent observational findings [6]. Effective
pharmacology treatmentsmay be limited by various factors
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such as patient adherence, physician inertia, inadequate
doses, inappropriate combinations of anti-hypertensive
drugs, non-compliance with dietary restrictions, side effects
of medications and drug ineffectiveness [7–9]. Thus, the
development of new approaches for the management of
hypertension that could potentially overcome these issues is a
priority, especially for patients with so-called resistant
hypertension, i.e. patients unable to achieve target blood
pressure values despite multiple drug therapies at the
highest tolerated dose and are at a high risk of major
cardiovascular events [10,11]. A variety of studies have been
performed, which suggests that hyper activation of the
sympathetic nervous system plays an important role in
initiating and maintaining hypertension [7,12,13]. Studies
of renal denervation in animals performed using surgical
and chemical techniques, have also further helped to
establish the roles of renal sympathetic nerves in
hypertension [14,15].
Recently, clinical studies in human patients have been
performed to assess the safety and efficacy of a percutane-
ous catheter based approach (SymplicityTM, Medtronic,
CA) [10,16]. In this procedure, a specially designed
catheter is inserted into the femoral artery, advanced
into one of the renal arteries and the radio frequency (RF)
energy is applied to the endoluminal surface to deliver
thermal injury to the renal sympathetic nerves. In a safety
and proof of principle study and in a separate randomized
trial, this approach was shown to reduce blood pressure
successfully, without serious adverse events in patients
with resistant hypertension [10,16]. Durability of treat-
ment effect up to two years has also been reported in a
cohort of 153 patients with resistant hypertension treated
using the catheter based RF denervation technique [17].
Recent publications have also confirmed the efficacy of
renal denervation for the treatment of resistant hyperten-
sion [18–20].
Although well received by clinicians, there are limita-
tions of renal denervation using the RF technique.
Procedural limitations include the catheter instability,
triggering frequent treatment interruptions, and the
overall duration of the procedure, which consists of a
minimum of eight 2 minute ablations, the time required to
reposition the device continuously and the associated
patient discomfort or pain [21]. While further research is
necessary to assess long-term safety and efficacy of RF
denervation, an underlying mechanism to cause renal
denervation using RF has been attributed to a localized
temperature rise or hyperthermia [22]. Morphological
assessment of porcine renal arteries after RF denervation
show acute transmural tissue coagulation and loss of
endothelium resulting in local thrombus formation [23].
Vascular smooth muscle cells express what is called tissue
factor (TF), a protein on their surfaces. Endothelial cells
cover the smooth muscle cells in the renal artery
preventing exposure of TF to proteins in the blood that
initiate the clotting cascade. When endothelial cells are
killed and removed from the wall, TF becomes accessible to
clotting factors often resulting in thrombus formations [24–
26]. While long-term studies of RF renal denervation claim
almost completely re-endothelialized lumen [23], a treat-
ment modality for renal denervation minimizing the
duration of treatments and the acute loss of endothelium
would still be desirable.
The experience with thermal injury to the endothelium
and other non-target tissues has generated an interest in
the exploration of alternative ablative energy forms.
Recently, ultrasound therapy has been investigated as
an alternate suitable modality for denervation of renal
nerves [21,22]. Clinical trials have also been performed
investigating the use of ultrasound (ParadiseTM, ReCor
Medical, NY) for renal denervation. A percutaneous
catheter based approach is used and consists of a
cylindrical transducer that emits ultrasound energy
circumferentially, once in the renal artery. Awater balloon
in the catheter is used to center the transducer in the
artery and to cool the arterial wall to minimize damage to
the endothelium and non-target tissue. Preliminary
clinical studies using this technique have been performed
on a cohort of 11 patients and indicate ultrasound therapy
to be a promising treatment for resistant hypertension. In
this case, an average of 5.1 ultrasound emissions was
delivered in each subject for a total treatment duration of
about four minutes [21].
Laser treatments are an alternative energy formwidely
used for a variety of medical therapeutic and diagnostic
applications [27]. The recent availability of fiber coupled
laser devices with sufficient average powers have led to
the development of minimally invasive catheter based
medical treatments [27–30]. Fiber lasers are potentially
advantageous for renal denervation over other ablation
techniques for the following reasons. First, fiber coupled
lasers are available in high average powers (>40W) and
can be easily focused or collimated. Depending on the
treatment delivery method (focused or collimated), the
treatment site can be better confined and the total treat-
ment time is likely to be less than both RF and ultrasound
techniques, helping to reduce patient discomfort and pain
during the procedure. Second, treatments using a focused
laser set up could help in creating a temperature gradient
along the depth of the treatment site, making it possible
to damage target structures like the renal nerves with
minimal injury to non-target structures like the endothe-
lium without the use of an external cooling mechanism.
Also, compared to RF and ultrasound with high penetra-
tion depths (>1 cm), the laser penetration depths can be
easily limited by using the right wavelength, such that the
depth of damage extends only as deep as that required to
reach the renal nerves and ensures that the abdominal,
pelvic or lower extremity nerves are unaffected. Finally,
selective tissue damage using specific laser wavelengths
have also been investigated in literature [31,32], which
could prove to be attractive for causing selective nerve
damage for renal denervation.
In this work, we present experimental results, which
show that lasers are an attractive energy source for renal
denervation. In vitro renal denervation using a focused
980nm laser is performed in porcine and ovine renal
arteries, where the histochemical analysis show that by
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optimizing the treatment conditions, it is possible to
damage the renal nerves without causing injury to the
endothelium and part of the media. Then, we investigate
the use of lasers at the lipid absorption lines, 1210nm and
1700nm, to cause selective damage to the renal nerves by
targeting the lipid rich myelin sheaths surrounding the
nerves. Next, in vivo renal denervation using a focused
980nm laser is performed in sheep using a specially
designed laser catheter and the histochemistry results
show clear evidence of renal nerve damage with depths
of damage extending >1.5mm from the artery wall
following a five second laser treatment. Evidence of
adventitial damage at depths of >1mm from the artery
wall without injury to the endothelium and part of the
media are also observed in some sections. Finally, we
discuss possible improvements in the catheter design to
provide better control of the position and treatment
parameters inside the renal artery. Selective damage
issues and other potential advantages of using lasers for
renal denervation are also discussed before ending with
our conclusions.
MATERIALS AND METHODS
This section is organized as follows. We first discuss the
choice of wavelengths at 980nm, 1210nm, and 1700nm
for renal denervation based on the tissue absorption
spectra and penetration depth calculations. Then, we
provide details for the in vitro renal denervation
experiments using a focused laser beam at the three
wavelengths. Next, we explain the 980nm laser catheter
prototype design used for the ovine in vivo renal
denervation experiments followed by details of the animal
interventional procedures and the histochemistry protocol
used to visualize live versus killed tissue for all samples in
this paper.
Wavelength Selection and Penetration Depth
Calculations
The primary requirement for the choice of wavelength is
that it should be able to penetrate at least up to the depth in
tissue to cause damage to the renal nerves, majority
(>75%) of which are within 1.5mm from the lumen wall
in humans [13]. In addition, it might be possible to cause
selective damage to the nerves using specific laser
wavelengths that target the nerves or nerve components
with little or no damage to the non-target tissues. For
example, wavelengths with strong lipid absorption could
potentially target the lipid rich myelin sheaths [33] that
surround the nerves and cause nerve injury with minimal
collateral tissue damage.
For penetration depth calculations, we use the Beer’s
law in anisotropic media, where the fluence f(z) falls
exponentially with depth as given by fðzÞ ¼ f0expðmef f zÞ;
ma is the magnitude of the absorption coefficient,m
0
s is the
reduced scattering coefficient and m
0
s ¼ ms 1 gð Þ, where ms
is the scattering coefficient and g is the anisotropy
coefficient. The reduced attenuation coefficient (meff) and
penetration depth (d) are then calculated using the
following formulas [34,35]:
mef f ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3maðma þ msð1 gÞÞ
p
if ma << ms ; ma < m
0
ð1Þ
mef f ¼ ma þ msð1 gÞ if ma  m0 ð2Þ
d ¼ 1=mef f ð3Þ
The penetration depth is defined as the distance atwhich
the fluence is reduced to 1/e of the incident value and is
equal to 1/meff. Since the tissue is mostly water, we assume
for our calculations that the tissue absorption character-
istics are similar to water. Since, scattering properties
in the near infrared wavelengths are well documented
for the dermis (compared to arterial tissue), we have
used scattering coefficients in the dermis to calculate
and compare the estimated penetration depths at the
three wavelengths used in this study. Figure 1 shows
the absorption spectra for water [36] and fat [37] and the
scattering coefficient in the human dermis (http://omlc.
ogi.edu/news/jan98/skinoptics.html; 1998). As seen in
Figure 1, wavelengths around 1700nm and 1210nm
are attractive for targeting lipid rich structures such as the
myelin sheaths surrounding the renal nerves and at the
same time are near relative water absorption minima,
allowing for good penetration depths. On the other hand,
980nm is an attractive wavelength for even deeper
penetration depths, since it has the lowest water absorp-
tion of the three wavelengths, and is easily available in
fiber coupled modules with high average powers of >30W.
Table 1 shows the calculated attenuation coefficients
and the penetration depths in tissue at 980nm, 1210nm
and 1700nm, respectively. The penetration depths in
tissue are calculated using equations [1–3] to be 2.7mm,
Fig. 1. Infrared spectra showing the coefficients for water (ma)
and human fat absorption and effective scattering in the
dermis (m0s).
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1.9mm, and 1.1mm for 980nm, 1210nm, and 1700nm
respectively.While all threewavelengths have penetration
depths of >1mm, only 980nm and 1210nm have the
required penetration depth of> 1.5mm to damagemajority
of the renal nerves. Thus, the calculations presented here
suggest that 980nm and 1210nm laser are more suitable
for renal denervation than 1700nm due to the deeper
penetration depths. However, 1700nm is potentially
capable of causing more selective damage to the renal
nerves than 1210nmdue to the higher lipid absorption and
is included in our in vitro studies. Therefore, based on the
penetration depths and potential for selective damage, the
three wavelengths that we study for renal denervation in
this paper are 980nm, 1210nm, and 1700nm.
Table 2 shows a summary of the laser sources used in the
renal studies. The 980nm (IPG, USA), 1210nm (QPC,
USA), and 1700nm (QPC,USA) lasers are all commercially
available fiber coupled laser diodes. The 980nm laser diode
fiber has a core/cladding diameter of 105/125 microns,
0.22 fiber NA and a maximum output power of 30W. The
1210nm laser diode fiber has a core/cladding diameter
of 400/440 microns, 0.22 fiber NA, and maximum output
power of 12W. The center wavelength is specified as
1211.76nm with a spectral full width at half maximum
(FWHM) of 4.59nm at full power. The 1700nm laser diode
also has a core/cladding diameter of 400/440 microns, 0.22
fiberNA, and amaximumoutput power of7W.The center
wavelength is specified as 1694nm with a spectral width
FWHM of 12nm at full power.
Treatment Setup for In-Vitro Renal Denervation
Experiments
The set upused for in vitro renal experiments is shown in
Figure 2. An aspheric lens is used to focus the laser beam
from the fiber output and the 1/e2 beam diameters along
the beam are calculated using knife-edge measurements.
The sample is mounted onto a sample holder attached to a
computer controlled stepper motor stage with a minimum
step size of 1 microns and scanned across the laser beam.
Scanning is done in order to increase the area of laser
treatment to maximize the chances of observing a laser
affected nerve region after performing the sectioning and
histochemistry analysis. For all in vitro experiments
presented in this article, the scan speed is arbitrarily set
to 0.4mm/s and the incident power levels are optimized
for the desired damage profile based on the histochemical
analysis results.
In vitro renal denervation experiments are performed
using both porcine and ovine renal arteries.Majority of the
renal nerves (75%) in humans are within 1–1.5mm
from the artery wall. In our studies, we mimic this in vivo
dimension, where the effects of blood pressure thin the
lumen wall thickness and bring the nerves closer to
the wall, by stretching the in vitro renal artery samples so
that distance for the tissue top (lumen wall) to bottom
(around the nerves) is 1.3mm. This is done by stretching
the tissue sample between two glass slides with a1.3mm
spacer in between. Thus, for all the in vitro renal
denervation, the thickness of the sections from the lumen
wall to the bottom of the section is  1.3mm during the
laser treatments. The in vitro denervation histochemistry
results have a true/actual scale length included for
comparison between sections, but is not an accurate
representation of the depth during treatments.
The entire kidney and arteries alongwith a piece of aorta
are obtained from a local butcher shop, kept in Dulbecco’s
TABLE 1. Estimated Penetration Depths in Tissue for
980 nm, 1210 nm and 1700 nm
Wavelength
(nm)
ma
(cm1)
m
0
(cm1)
meff
(cm1)
d
(mm)
980 0.5 8.5 3.7 2.7
1210 1.3 5.8 5.3 1.9
1700 6 3 9 1.1
TABLE 2. Details of Laser Sources Used for the Renal Denervation Studies
Laser
Source
Max
Power
(W)
Center
Wavelength
(nm)
FWHM at
Full Power
(nm)
Fiber Core/
Cladding Diameter
(mm)
Fiber
NA
980 nm 30 976 – 105/125 0.22
1210 nm 12 1211.76 4.59 400/440 0.22
1700nm 7 1694 12 400/440 0.22
Fig. 2. Experimental setup used for the in vitro renal denervation
studies using a focused laser beam.
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modified eagle medium (D-MEM), high glucose 1X (from
GIBCO, CA), and transported to the laser lab within hours
of extraction, where they are stored in a refrigerator at
5–78C, until the experiments are performed. The samples
are kept in a warm water bath at 378C for about an hour
prior to the laser treatments. All treatments are performed
less than 48 hours after obtaining the samples. For the in
vitro experiments, the renal artery is cut into 3–4 sections
and each section is then scanned across the laser with the
beam incident on the lumen wall. Figure 3 shows an
example,where the renal artery is extracted, sectioned and
prepared for the in vitro laser treatments.Frozen sections
of treated renal artery tissues are prepared and histo-
chemical analysis is performed using the methylthiazo-
lyldiphenyl-tetrazolium bromide (MTT) assay to identify
laser damage in the sections [31].
Catheter Design for In Vivo Renal Denervation
The catheter distal end design used for the ovine in vivo
studies is shown in Figure 4 and consists of five main
components: a glass ferrule to hold the fiber output, an air
gap to adjust focal length, a GRIN lens to focus the light, a
right angle prism, and an outer steel tube enclosure. The
final distal end is less than 1 cm in length and has an outer
diameter (OD) less than 2.2mm.
The first component is the glass ferrule, which is used to
hold the optical fiber in place. The glass ferrule has an OD
of 1.8mm and ID of 0.129mm to fit the 0.125mm
cladding fiber and is polished down using a diamond
grinder to a length of 2.2mm to fit within our required
length specifications. Figure 4 inset shows an example of a
standard fiber-glass ferrule and a finished product. The
fiber is held in place inside the ferrule using UV cured
optical adhesive.
The next component is the air gap spacer between the
fiber and the GRIN Lens (Edmund Optics, #64532, NJ).
The focal distance between the outer steel tube and the
focus is determined by adjusting the distance between the
fiber end and the GRIN lens. The spacers are hypodermic
steel tubes precision machined down to specific lengths.
The spacer tubes have an OD of 1.65mm and an ID of
1.58mm. A GRIN lens is the focusing optic in this
catheter design and has an OD of 1.8mm and a length of
4mm. Figure 5a shows the simulation results (using
ZEMAX) for the range of focal lengths in tissue obtained
using this GRIN lens for various air gap spacer lengths.
Thus, a range of focal lengths can be obtained by adjusting
the spacer lengths between the fiber and the GRIN lens.
Figure 5b also shows the calculated beam diameters at the
distal end output and at the focal spot. The distal end is
assumed to be in contact with the artery wall and the
refractive index in tissue is assumed to be 1.38 for the
simulations.
The next component is the right angle prism (Tower
Optical Corporation, FL) used to rotate the light by 90
degrees towards the renal arterywall. The prism ismade of
glass and the hypotenuse is aluminum coated to act like a
mirror. The prism is glued on to the GRIN lens using UV
cured optical adhesive.
The outer tube is the final component and holds all the
optical components together. The hypodermic steel tube is
Fig. 3. Extraction of the renal artery and sample preparation for the in vitro experiments. The
renal artery is first identified and extracted (A, B). The artery is then cut open, sectioned and
prepared for laser treatments (C, D).
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8.5mm long and has an ID of 1.8mm and an OD of less
than 2.1mm.The prism is protected by the outer tube and a
2mm wide opening at the end of the tube allows the light
from the prism to exit. The distal end and fiber is pushed
though a braided polyimide tubing and glued to the metal
outer tubing. The finished catheter is then guided through
a 5 French (F) FR4 catheter to help provide stronger push
ability in combination with the polyimide tubing. A Tygon
tube model of the sheep aorta (1 cm diameter) and renal
artery (0.5mm diameter) are made to test and verify that
the final catheter is able to fitwithin these dimensions. The
fiber end is connectorized with an SMA connector to allow
for a convenient connection with the laser source during
treatments. The entire finished catheter is then packaged
and sterilized using ethylene oxide prior to the in vivo
experiments.
The current catheter prototype does not have any
maneuvering ability once inside the renal artery. Thus,
Fig. 4. Distal end design for the catheter used to deliver the in vivo treatments.
Fig. 5. ZEMAX Simulation results of the distal end performance in tissue (A) Outer tube–focus
distance vs. the air gap length. (B) Estimate of the beam diameters at the distal end output and at
the focus. The distal end is assumed to be in contact with the tissue.
694 ALEXANDER ET AL.
we are not able to adjust the position such that the
catheter is in the optimum position in the artery during
the laser treatments. Since the treatments use a focused
laser beam in order to damage the nerves with minimum
impact on the endothelium, it is important for the focus to
be close to the location of the renal nerves, majority of
which lie in 1–1.5mm region from the renal artery wall.
One optimum condition for our treatment is for the distal
end tomake contact with the arterywall and then have the
laser focus be at1.5mm. Since, we are not able to control
the distal end position once inside the artery; we use two
catheter distal ends, each with a different focal length to
improve our chances of getting close to the optimum
condition. For the in vivo experiments, the two focal
lengths in tissue (outer tube to focus) for the two catheters
are estimated to be 2.80.3mm and 3.80.3mm,
respectively. The focal length measurements are per-
formed in air and estimated using an aperture. The
average diameter of the renal artery in sheep/goat is
5mm (range from 4 to 6mm) and this choice of focal
lengths might allow us to penetrate deep enough to
achieve renal nerve damage and possibly save the
endothelium as well. It is worth mentioning that we
choose the two focal lengths to maximize our chances of
getting close to the ideal condition of focusing close to the
nerves, but the best way to guarantee this is to use a
specifically designed catheter delivery system that is able
to control and maneuver the position of the distal end
within the renal artery cross section. Catheter design
improvements are further explored in the discussion
section.
Animal Interventional Procedures
The animal use protocol was reviewed and approved by
theUniversity Committee for theUse andCare of Animals.
Three female adult sheep weighing 51–60kg are used for
the renal studies. The sheep are fasted for 24 hours prior to
the procedure to aide in decreasing incidents of bloat,
regurgitation, and to increase visualization during fluo-
roscopy. Each sheep is given pre-op Xylazine, 0.2mg/kg
intramuscular, to aide in calming the animal for restraint.
An 18 g angiocatheter is placed in the cephalic vein,
secured in place, and flushed with heparinized saline.
Propofol, 4–6mg/kg intravenous, is then administered for
anesthetic induction and to aide in endotracheal intuba-
tion. A 10–11mm endotracheal tube is used for intubation.
The animals are then placed on oxygen and isoflurane
anesthesia using an adult unilimb breathing tube and
3–4L rebreathing bag. Ophthalmic ointment is placed in
the eyes. The analgesics Buprenorphine 0.01mg/kg
intramuscular and Carprofen 4mg/kg subcutaneous are
given to aide in alleviating postoperative pain and
swelling. The antibiotic Cefazolin 22mg/kg intravenous
is administered pre-operatively for prophylactic measures.
The animals are then transferred to the operating suite
and placed on a fluoroscopy table in ventro-dorsal position.
A Surgivet Advisor is utilized to monitor non-invasive
blood pressure, EKG, pulse rate, oxygen saturation,
respiratory rate, body temperature, and end tidal carbon
dioxide. Reflexes are checked periodically. Lactated ring-
ers are given intravenously at 10ml/kg/hour throughout
the procedure. A rumen tube is placed and maintained
during the procedure to aide in the prevention of bloat and
regurgitation of rumen contents.
Prior to the laser treatments, a 6 F sheath is inserted in
the right femoral artery after application of Lidocaine.
A perclose device is used to pre-close the artery [38]. An 8 F
45 cm arrow sheath is then introduced through the
arteriotomy. Heparin in the dose of 100 IU/kg was
administered. Through the arrow sheath, a 5 French
FR4 or an IMA catheter is used to engage the renal artery.
ARosenwire is then advanced into the renal artery and the
diagnostic catheter (FR4 or IMA) is advanced into the renal
artery. Over the wire and the diagnostic catheter, the
arrow sheath is advanced into the distal renal artery. The
diagnostic catheter and the wire are removed and the laser
catheter gently advanced out of the sheath and up to the
renal artery bifurcation if possible. The treatment time is
arbitrarily set for five seconds and the laser power
delivered is varied over a range of power levels. All power
levels reported are measured power at the fiber output.
The catheter and sheath is slowly withdrawn back in steps
of approximately 5mm and treatments provided until the
catheter is in the aorta. Attempts are made to turn the
catheter as it is withdrawn with the intent of providing
treatment along a spiral, but this could not be reliably
done. All three animals survived the procedure and were
allowed to recover for 24 hours post laser treatment.
The sheep are sedated with 0.3mg/kg intramuscular
Xylazine and humanely euthanized 24 hours after the
laser procedure with intravenous sodium pentobarbital at
a dose of 1ml/4.5 kg body weight. The sheep are placed in
left lateral recumbency and the body wall is opened.
Surrounding viscera is removed, exposing the kidneys and
abdominal aorta. The abdominal aorta and vena cava are
incised cranial and caudal to the branch points of the renal
arteries and veins, allowing removal of the kidneys and
their major vascular attachments en bloc. The renal
arteries are finely dissected from the attachments at the
abdominal aorta and the renal hilus. A thin layer of
adventitial adipose tissue is retained with the renal
arteries to avoid inadvertent damage of small adventitial
blood vessels (vasa vasorum).
The harvested renal arteries are placed in optimal
cutting temperature compound (OCTTM), frozen in liquid
nitrogen and stored at 808C until frozen sections can be
cut. Total time from euthanasia to renal artery placement
in media is approximately 20–30 minutes. Cryostat-cut
sections are made and mounted on glass slides, and stored
at 808C until used for histochemical staining of dehydro-
genase activity. To identify laser damage in the processed
sections, we use the MTT histochemical assay, a proxy for
dehydrogenase enzyme activity for cell viability [31]. Cells
that are alive when frozen maintain dehydrogenase
activity, but cells that are dead do not have this activity.
In live cells that are frozen, dehydrogenase activity
reduces the slightly yellow water soluble MTT substrate
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into a water insoluble dark blue to black precipitate. Thus,
in the MTT histochemical assay, live cells stain dark blue
while dead cells remain clear. The volume of incubation
medium is adjusted proportionally depending on the
number of sections to be stained. The sections are
immersed in MTT incubation medium under aerobic
conditions with no ambient light for about 30 minutes,
rinsed in DI water and dried afterwards. The sections are
examined using a microscope (WILD Makroscop M420)
and photos are taken using a digital camera (NIKON
Coolpix 5000).
EXPERIMENTAL RESULTS
In vitro results at 980nm, 1210nm, and 1700nm are
presented first, followed by in vivo results at 980nm using
the designed laser catheter prototype.
In Vitro Laser Renal Denervation using a Focused
980nm Laser
In-vitro renal denervation studies using the focused
laser set up at 980nm are performed in both porcine and
ovine renal arteries. The renal arteries are exposed to a
range of incident power levels, causing anywhere from
little or no damage to complete damage of the entire artery
section. In each case, the artery tissue is stretched during
laser treatments so that the top to bottom thickness is
1.3mm, and the beam diameters on the tissue top (artery
wall) and tissue bottom (adventitia) are estimated to be
1.2mm and 0.4mm respectively.
TheMTT histochemistry results for porcine renal artery
cross sections treated over a range of incident power levels
at 980nm are shown in Figure 6. Figure 6A shows an
example where the treatment parameters (1.5W, 0.4mm/s
scan) are inadequate to cause any damage to the renal
artery tissue. Figure 6B shows an example of the optimum
treatment condition (1.8W, 0.4mm/s scan), where we are
able to observe renal nerve damage with no injury to the
endothelium and finally, Figure 6C shows a treated artery
section where the power level (3W, 0.4mm/s scan) is high
enough to cause transmural damage to the entire renal
artery tissue section from top to bottom at the treatment
site. Thus, the results presented in Figure 6 show that by
optimizing the laser treatment parameters, a focused laser
beam at 980nm can achieve renal nerve damage with little
to no injury to the endothelium and part of the media.
Adult sheep are used as the animal model for our in vivo
trials, since the aorta and artery diameters in sheep are
closer in dimension to humans. Renal studies have also
been reported in literature using the sheep as the animal
model [39]. Therefore, in addition to the in vitro treatments
in porcine renal arteries shown in Figure 10, we also
performed in vitro renal denervation experiments in ovine
renal arteries using the 980nm [not presented in this
article]. TheMTT histochemistry results in sheep are seen
to be consistent with in vitro porcine renal denervation
results from Figure 10 and clearly show that a focused
laser beam at 980nm can be used to damage the renal
nerves with little to no injury to the endothelium and part
of the media. As an added advantage, 980nm lasers are
also commercially available in fiber coupled diode modules
with average powers of> 30W.
In Vitro Laser Renal Denervation Using Focused
1210nm and 1700nm Lasers
Laser sources near 1210nm and 1700nm are of interest
for medical applications due to the higher absorption
coefficient of lipids compared to that of water at these
wavelengths, which suggests that it might be possible to
selectively target lipid rich tissueswithminimal damage to
the surrounding non-target tissues using these wave-
lengths [31,32,37]. Since the myelin sheaths surrounding
the nerves are rich in lipid content, it might be possible to
selectively cause renal nerve damage with minimal
damage to the surrounding tissues using lasers with
wavelengths around 1210nm and 1700nm.
In-vitro renal denervation studies at 1210nm and
1700nm are performed in porcine renal arteries using
the focused laser set up, where the renal arteries are
exposed to a range of incident power levels, causing
anywhere from little or no damage to complete damage of
the entire section. In each case, similar to the previous
section, the artery tissue is stretched during laser treat-
ments so that the top to bottom thickness is 1.3mm, and
the beam diameters on the artery wall (tissue top) and
Fig. 6. In vitro porcine renal denervation results using the focused laser setup at 980nm showing
(A) insufficient damage (1.5W, 0.4mm/s scan), (B) Optimum condition with renal nerve damage
without injury to the endothelium and part of the media (1.8W, 0.4mm/s scan) and (C) Excess
damage with injury along the entire tissue depth (3W, 0.4mm/s scan).
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adventitia (tissue bottom) are estimated to be1.2mmand
0.4mm, respectively.
Figure 7 shows the MTT histochemistry results for
porcine renal artery cross sections treated with the both
wavelengths over a range of incident power levels. For each
wavelength, the first column shows an example where the
treatment power is inadequate to reach the nerves, the
middle column shows an example of the optimum condi-
tion, where we are able to observe nerve damage with little
to no injury to the endothelium, andfinally, the last column
shows an example, where the power level is high enough to
cause transmural damage to the entire section from top to
bottom at the treatment site. For example, Figure 7(A, B,
C) shows the histochemistry results for treatments with
the 1210nm laser. Slight tissue damage is observed in
Figure 7A (1.5W, 0.4mm/s scan). In Figure 7B (1.8W,
0.4mm/s scan), we see clear evidence of nerve damagewith
little to no damage to the endothelium. Fig 7C (2.1W,
0.4mm/s scan) shows a section, where the higher incident
power causes transmural damage at the treatment site.
Similarly, Figure 7(D, E, F) shows the histochemistry
results for artery sections treated with the 1700nm
laser.
The results in Figure 7, show that both 1210 nm and
1700 nm lasers are capable of causing renal nerve
damage, with little to no injury to the endothelium and
part of the media. However, the 1700nm laser is only
capable of causing partial nerve damage due to the higher
absorption and lower penetration depth in tissue at this
wavelength. The results shown in Figure 7 also do not
show any clear evidence of selective nerve damage using
current laser treatment parameters at 1210 nm and
1700nm. Selectivity issues are further explored in the
discussion section.
For the focused denervation experiments, Beer’s law
and the focus advantage are countering effects, i.e. if the
absorption is high, then most of the light will be absorbed
close to the lumen and not be able to penetrate deep
enough to reach the nerves making the focusing advan-
tage less useful. This can be further understood using a
simple 1D Gaussian beam model taking into account both
the effects of focusing, absorption, and scattering. The
laser intensity distribution with tissue depth can be
estimated by:
Iðr; zÞ ¼ Ipeakeð2r2=w2ðzÞÞeðmef f zÞ
where
IpeakðzÞ ¼ 2 Pinc
pw2ðzÞ
Pinc is the incident power on the tissue surface, w(z) is
the beam waist radius. For a converging laser beam of
radius R0 at the tissue surface, focused at a depth z¼FD
with a beam radius of RD at the focal spot, the beam waist
Fig. 7. In vitro porcine renal denervation results using the focused laser setup at 1210nm (A,B,C)
and 1700nm (D, E, F), scanned at 0.4mm/s. Three cases are shown for each wavelength The first
column shows inadequate damage. The middle column shows the optimum treatment condition
achieved for eachwavelengthwith laser damage to the nerves andno injury to the endothelium. The
third column shows treatment power levels high enough to cause transmural damage extending
across the entire section depth.
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(w(z)) with depth can be estimated by the following
expression:
wðzÞ ¼ R0
ðRD  R0Þz
R0 FD þ 1 if 0  z  FD
ðR0 RDÞz
R0 FD 
ðR0 2RDÞ
R0
if z > FD
0
BB@
1
CCA
For the in vitro experiments shown in Figures 6 and 7,
The values for R0 and RD are 0.6mm and 0.2mm,
respectively. In the absence of absorption and scattering,
onewould then expect a peak intensity difference along the
beam center (r¼ 0) of 9 between the endothelium and
the renal nerves. Once the effects of absorption and
scattering (from section “Wavelength Selection and Pene-
tration Depth Calculations”) are taken into account, the
intensity difference factor drops to 6 for 980nm, 4
for 1210nm, and 3 for 1700nm. Therefore, Beer’s law
and focusing advantage are seen to be countering effects
and a lower effective attenuation is expected to be better for
focusing applications at greater depths. Since 980nm has
the lowest effective attenuation, among three wavelengths
considered, we can then expect to achieve the greatest
intensity difference between the endothelium and the
nerves at this wavelength.
In Vivo Renal Denervation Using a 980nm Laser
A catheter-based approach (described in section “Cathe-
terDesign for in vivoRenalDenervation”) is used to deliver
the 980nm laser treatments to the renal arteries in sheep.
Two catheters with focal lengths of 2.8 0.3mm (FL1)
and 3.8 0.3mm (FL2) in tissue are used for the in vivo
renal denervation experiments. The laser output powers
range from 2.0 to 4.0W with a treatment time of five
seconds at each treatment spot. The treatments are first
administered in the renal artery section proximal to the
kidney and then moved progressively to the distal end
closer to the aorta. Figure 8 shows the fluoroscope images
of the laser catheters in the renal artery prior to the laser
treatments.
Figure 9 shows the MTT histochemistry for sections of
ovine renal artery treated with the 980nm laser (five
seconds exposure time) using FL1 at 3.5–4.0W (A, B), and
FL2 at 2.5–3W (C, D). In Figure 9 (A and B), we see a
distinct large nerve around the renal artery that is clearly
damaged, as evidenced by the lack of staining. The depth of
damage in this section is seen to extend> 1.1mm from the
artery wall. Figure 9(C and D) show another example,
where the renal nerves in the treatment site are not
stained and indicate thermal damage by the 980nm laser.
The depth of damage in this section is seen to extend
>1.5mm from the artery wall. The in vivo results
presented in Figure 9 clearly indicate that the 980nm
penetrates deep enough (>1.5mm) to cause thermal
damage to the renal nerves and that it is possible to
achieve renal denervation using this technique. Figure 9
also shows some sections with a circumferential damage
pattern, which could be the result of inadvertent catheter
movements inside the renal artery.
While both examples in Figure 9 show evidence of laser
renal denervation using the 980nm laser, the endothelium
is unstained as well indicating thermal injury. The laser
treatments are delivered in a focused beam with a
Gaussian profile, where the intensity is highest at the
beam center and increases towards the focus. The results
presented in Figure 9 show the endothelium to be damaged
as well indicating that the beam intensity delivered to the
artery wall must be higher than the damage threshold for
the endothelium andmedia. Since the position of the distal
end inside the renal artery cannot be controlled for our
current catheter prototype, one potential reason for
damage to the endothelium and media is that the focal
point is closer to the artery wall instead of the nerves and
there is a lack of sufficient laser intensity difference
between the artery wall and nerve site.
Focusing the laser beam at a depth close to the renal
nerves should allow for an intensity difference andhence, a
Fig. 8. Fluoroscope images of laser catheters in sheep in vivo (A) Catheter FL1, right kidney
(B) Catheter FL2, Left kidney.
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temperature difference between the tissue top, close to the
endothelium, and the tissue bottom, where the nerves are
located. Thus, a focused laser beam treatment should be
able to cause thermal damage to the renal nerves, while
sparing injury to the endothelium and part of the media.
Figure 10 shows examples of some sections from our in vivo
experiments, wherewe see histological evidence of thermal
damage in the media and adventitia without any damage
to the endothelium. However, in these cases, there are no
clearly identifiable renal nerves or the depth of damage
does not extend deep enough to damage the renal nerves.
Some possible reasons for the depth of damage not
extending deep enough could be that the laser treatment
power/exposure time may not have been sufficient and/or
the focal spot may not be near the nerves, but closer to the
media. While we have not observed in vivo histochemistry
results showing clear nerve damage without injuring the
endothelium, the results presented in this section show
that it is possible to achieve renal denervation in vivo
(Fig. 9) and the results presented in Figure 10 suggest that
the focused laser treatment can cause arterial damage at
depths>1mm without causing damage to the renal
artery wall including the endothelium and part of the
media.
DISCUSSION AND CONCLUSIONS
Renal denervation has recently become of great interest
as a potential treatment for resistant hypertension. The
current treatment modalities use either RF or ultrasound
therapy. Both of these techniques either cause endothelial
Fig. 9. MTT histochemistry of sections from in vivo trials showing complete renal denervation
with 980nm laser after treatment with (A, B) catheter FL1 3.5-4W, 5 second exposure and (C, D)
catheter FL2, 2.5-3W, 5 second exposure.
Fig. 10. In vivo MTT histochemistry examples showing laser damage to the media/adventitia
with no injury to the endothelium and artery wall after 980nm laser treatment with (A) catheter
FL1 3.5-4W, 5 second exposure and (B) catheter FL1, 2-2.5W, 5 second exposure.
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damage and local thrombus formation, or employ an
external cooling mechanism to minimize the artery wall
damage. In addition, their current energy delivery times
are greater than four minutes [10,21]. There is an interest
in exploring other energy forms for renal denervation that
could substantially reduce the treatment times as well as
minimize the damage to the endothelium and other non-
target arterial tissue. Lasers have been widely used for
medical ablation applications and have the following
potential advantages. First, the treatment times can be
significantly lower for laser treatments. The in vivo
histochemistry results using the 980nm laser presented
in section “In vitro Laser Renal Denervation using a
Focused 980 nm Laser” show that it is possible to damage
renal nerves using lasers and the treatment time at each
spot is only five seconds. With an estimated total of 4–6
treatment spots in each artery, the total energy delivery
time could be less than one minute for the denervation
treatments, helping to minimize patient discomfort and
pain. Second, as seen in the in vitro results using focused
laser beams in sections “In vitro Laser Renal Denervation
using a Focused 980 nm Laser” and “In vitro Laser Renal
Denervation using Focused 1210 nm and 1700 nmLasers”,
lasers can be easily focused to create an intensity gradient
across the artery section and allow saving the endothelium
and part of the media without using any external cooling
mechanism. Also, compared to RF and ultrasound with
high penetration depths (>1 cm), the laser penetration
depths as calculated in section “Wavelength Selection and
Penetration Depth Calculations” show that by using the
right wavelength, the depth of damage can be limited to be
only as deep as that required to reach the renal nerves and
ensures that the abdominal, pelvic or lower extremity
nerves are unaffected.
Another advantage of using lasers is the potential for
causing selective tissue damage by choosing the appropri-
ate wavelengths. Since the myelin sheaths surrounding
the nerves are rich in lipid content, it might be possible to
selectively target the myelin sheaths to damage the renal
nerves. As shown in Figure 1, both 1700nm and
1210nm are close to strong lipid absorption lines.
However, the ratio of the absorption coefficient for water
and lipids is still small at these wavelengths. Our
preliminary in vitro work in renal arteries comparing
these wavelengths as shown in section “In vitro Laser
Renal Denervation using Focused 1210 nm and 1700 nm
Lasers”, show that 1700nm may not have the necessary
damage depth to reach the renal nerves at 1.5mm
without causing endothelial damage as well. We also did
not observe any significant selective advantage of using the
1210nm and 1700nm over the 980nm laser treatments. It
is worth mentioning that the lipid absorption peak (from
Fig. 1) is closer to 1720nm and better selectivity might
be achievable closer to this wavelength. However, the
penetration depth will decrease further as we move closer
to 1720nm due to the higher water absorption. Increased
selectivity at 1210nm and at 1700nmmight be achievable
by using altered pulse durations. For example, Sakamoto
et al has reported selective damage to sebaceous glands in
human skin with external cooling using a pulsed 1720nm
laser [32]. The optimal pulse duration for selective damage
should be made shorter than or equal to the thermal
damage time (defined as the time required for irreversible
damage with sparing of the surrounding tissue) and is
dependent on the target tissue structure and size (d). The
thermal damage time is a function of the thermal
relaxation time, t ﬃ d2=27k[40], where kis the thermal
diffusivity constant [40] and can be many times as long as
the relaxation time of the target [41]. The nerve size and
distribution varies significantly, from <100mm to >1
mm[22] and assuming ak of 1:3 103cm2/s similar to [40],
this corresponds to a thermal relaxation times ranging
from 3ms to 300ms across the cross section of the renal
artery. Thus, the significant variations in nerve dimen-
sions across the cross section of renal arteries might make
selective denervation more challenging.
The in vitro experiments for renal denervation in
sections “In vitro LaserRenalDenervationusing aFocused
980 nm Laser” and “In vitro Laser Renal Denervation
using Focused 1210 nm and 1700 nm Lasers” also suggest
that wavelengths with lower tissue absorption might be
more beneficial to leverage the focusing advantage and
achieve denervation without damaging the endothelium.
From this perspective, other wavelengths with lower
tissue absorption, such as 1064nm lasers could possibly
be an even better candidate for renal denervation.
However, the lower tissue absorption would also require
a higher energy delivery to cause sufficient thermal
alteration of the renal nerves and include the risk of
causing damage beyond the intended tissue depths.
The in vivo results presented in section “In vivo Renal
Denervation using a 980nm Laser” clearly show histologi-
cal evidence of renal nerve damage after treatment with
the 980nm laser. However, the endothelium and artery
wall is also injured in the current process. One of themajor
limitations in our animal trials is the catheter capabilities.
The catheter prototype used in the in vivo trials currently
does not have any maneuvering ability, once inside the
renal artery. Thus, it is not possible for us to reliably know
the position of the distal end within the artery and
maneuver it such that it is at a known distance from the
vessel wall. In our treatments, the same catheter depend-
ing on its location within the cross section of the vessel,
could be focusing the light at the adventitia at one
treatment spot and in the lumen at the other. In addition,
a slight position change could result from a change in
catheter position, respiratory movements of the kidney or
even the pulsality of blood flow. The catheter movement
could also result in inadequate exposure times and/or the
overlap of treatment sites leading to insufficient damage
or excessive damage at the treatment site. For example,
the histochemistry results in Figure 9 seem to suggest a
possible treatment spot overlap or distal end movement
during treatment as evidenced by an almost circumferen-
tial damage profile. In addition, the actual power
levels delivered to the artery wall could also depend on
the amount of blood between the distal end and the artery
wall.
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Cathetermaneuverability inside the renal artery plays a
crucial role for renal denervation treatments including
current treatments that useRFandultrasound therapy. In
these treatment modalities, the position of the catheter
distal end is critical to obtain the desired results, since the
power, exposure times and the required penetration are
dependent on the distance between the energy source and
the artery wall. One possible solution to fix the position of
our laser catheter inside the renal artery is to use a
technique similar to the RF treatments (http://www.
medtronicrdn.com/intl/healthcare-professionals/symplic-
ity-rdn-system/index.htm), where the laser distal end
would be kept in contact with the renal artery wall prior
to the laser treatments. The distal end contact with the
artery wall can be monitored using the impedance
measurements currently used in RF treatments. It might
also be possible to ensure wall contact by monitoring the
back reflection of laser light from the catheter. As the distal
end gets closer to the artery wall, the light reflected back
into the distal end from the artery wall will increase as
well, which could be used to identify the position of the
distal end within the artery. Another potential solution is
to have the distal end enclosed in water or saline cooled
balloon in contact with the artery wall, which would then
enable the laser to be at a fixed distance from the artery
wall while cooling the arterywall during treatments. As an
example, laser treatments utilizing external cooling
mechanisms have been successfully demonstrated in
human skin to damage sebaceous glands at depths of
1.65mm from the epithelium, while saving the top
>0.5mm of the skin tissue from laser damage [31].
Therefore, the combined effect of cooling and focusing
has a high potential to minimize endothelial and non-
target tissue damage during the laser renal denervation
treatments.
Since the exact position and distribution of the nerves
within the renal artery during treatments are unknown,
current denervation techniques use an algorithm to deliver
treatments in a circumferential manner to ensure that
the nerves are damaged. The laser treatments could be
delivered circumferentially using a rotating mirror or
mirror designs, where the incident light is split into a
circumferential beam [42], which can then be used to
damage the renal nerves and reduce treatment times
further. In addition, it might be possible to image and
detect the position of the nerves prior to the treatments.
Catheter based OCT techniques are currently in existence
and have been developed for arterial imaging, with
penetration depths of 2–3mm [43]. It remains unclear
whether it is preferable to tailor the ablation to the
proximal renal artery, where there are fewer larger nerve
trunks or to the distal vessel, where there are more and
smaller nerves. With a proximal strategy, missing a large
nerve could compromise the therapeutic efficacy. On the
other hand, a distal strategy would require treatment
of a larger number of nerve targets to achieve complete
denervation [13]. In both cases, identifying the renal
nerves using an imaging technique like OCT, before laser
treatments could help to reduce the number to treatment
spots and improve efficacy by damaging a larger percent-
age of nerves while possibly avoiding unnecessary damage
to the artery, all of which could help to reduce patient
discomfort and pain.
In summary, we demonstrate a novel technique for renal
denervation using focused infrared fiber lasers. Histo-
chemical results for in vitro studies show that a focused
laser set up can be successfully used to cause renal nerve
damage without injuring the endothelium and part of the
media. Catheter based in vivo renal denervation treat-
ments in sheep using a 980nm laser are performed and
show clear evidence of renal nerve damage with depths of
damage extending> 1.5mm from the artery wall. Laser
induced damage to the media/adventitia at depths of
>1mm without injury to the endothelium are also
observed in vivo. The results presented in this article
indicate that lasers may offer a more efficient way to
achieve renal denervation by shortening treatment times
and minimizing damage to non-target tissues like the
endothelium. Further research and clinical studies using
lasers are warranted to determine the optimal treatment
parameters for renal denervation and to evaluate
their efficacy as a potential treatment for resistant
hypertension.
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